English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The effects of intravenously administered prostaglandin E1 (PGE1) on diabetic mononeuropathy was investigated in three patients with diabetic oculomotor palsy. PGE1 (1.0-1.5 micrograms/day) was intravenously administered every morning for 4 or 6 weeks. Diplopia, blepharoptosis and decreased range of ocular movement, which were observed on admission, immediately began to improve at 1-4 days after the beginning of the treatment. On the final day of the treatment, none of the above signs remained in the three cases. The present study suggests that improvement of intraneural microcirculation by PGE1 administration results in an immediate recovery from diabetic oculomotor nerve palsy.

Immediate improvement of diabetic mononeuropathy after intravenous administration of prostaglandin E1.